Life sciences partner Gregory Levine (Washington, D.C.) was quoted in an April 16 article in Bloomberg Law’s Life Sciences Law & Industry Report that discusses the U.S. Food and Drug Administration proposal for a more flexible approach to clear certain medical devices.
Mr. Levine notes the challenge will be getting specific medical devices qualified for inclusion in the new program. The FDA draft guidance does not make clear which devices would be eligible to use the new performance criteria.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.